Search hospitals
>
Maryland
>
Bethesda
National Institutes of Health Clinical Center, 9000 Rockville Pike
Claim this profile
Bethesda, Maryland 20817
Global Leader in Cancer
Global Leader in Healthy Subjects
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
Conducts research for Breast Cancer
3382 reported clinical trials
27 medical researchers
Summary
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Healthy Subjects, Lymphoma, Pancreatic Cancer, Breast Cancer and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,730 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Naoko Takebe.
Area of expertise
Cancer
National Institutes of Health Clinical Center, 9000 Rockville Pike has run 342 trials for Cancer. Some of their research focus areas include:
Healthy Subjects
National Institutes of Health Clinical Center, 9000 Rockville Pike has run 302 trials for Healthy Subjects. Some of their research focus areas include:
Top PIs
A P. Chen
National Institutes of Health Clinical Center
3 years of reported clinical research
Nirali N. Shah
National Institutes of Health, Clinical Center
9 years of reported clinical research
John Glod, MD
National Cancer Institute Pediatric Oncology Branch
9 years of reported clinical research
Naoko Takebe
National Institutes of Health Clinical Center
9 years of reported clinical research
Clinical Trials running at National Institutes of Health Clinical Center, 9000 Rockville Pike
Colon Cancer
Breast Cancer
Prostate Cancer
Cancer
Colorectal Cancer
Malaria
Stroke
Lung Cancer
Lymphoma
Aplastic Anemia
Genomic Services
for Secondary Findings in Genetic Testing
Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding. Objectives: To learn about how gene variants may affect a person s health. To learn about how people understand their genetic test results. Eligibility: People with secondary findings from genetic testing done as part of a research study, clinical care, or other methods. Design: Participants may be asked to do an online survey and phone interview to ask what they think about their results, their healthcare, and if they talk with their family about the result. Eligible participants may be offered a visit to the NIH Clinical Center where they will be evaluated for health problems related to the secondary finding. DNA samples that were already collected may be studied. Participants may be asked to send in a second DNA sample (blood or saliva). These will be used to verify any findings. Participants who have a secondary finding can get genetic counseling.
Recruiting
1 award
N/A
10 criteria
Ceralasertib + Trastuzumab Deruxtecan
for Solid Tumors
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
Recruiting
1 award
Phase 1
26 criteria
Gene Therapy Follow-Up
for Cancer
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate. Patients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study. Participants will be involved in the following forms of data collection: * Annual medical history and physical examinations for the first 5 years following the last vaccine. * Annual telephone contact during the last 10 years. * Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders. * Blood tests for the presence of HIV antibodies. * Reporting of medical problems, including information on unexpected hospitalizations and medications. If a participant has died, the study will document the cause of death and autopsy information if available.
Recruiting
1 award
N/A
2 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at National Institutes of Health Clinical Center, 9000 Rockville Pike?
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Healthy Subjects, Lymphoma, Pancreatic Cancer, Breast Cancer and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,730 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Naoko Takebe.
Where is National Institutes of Health Clinical Center, 9000 Rockville Pike located?
To reach the National Institutes of Health Clinical Center in Bethesda, Maryland: - From I-495 (Capital Beltway), take Exit 34 and head south on Route 355 (Wisconsin Ave./Rockville Pike). - Turn right onto West Cedar Lane, then left into the patient entrance on West Drive, open daily from 6 am to 10 pm. - Outside these hours, use the Commercial Vehicle Inspection Facility on Rockville Pike (Route 355) between North Drive and Wilson Drive, open daily from 10 pm to 6 am. Show a government-issued photo ID and follow signs to the "Clinical Center".
Who should I call to ask about financial aid or insurance network?
**National Institutes of Health (NIH) Clinical Center Contact Information:** - **General Inquiries:** (301) 496-4000 - **Study Assistance:** 1-800-411-1222 or 1-866-411-1010 (TTY) - **Cashier's Office:** 301-496-2654 - **Patient Representative:** 301-496-2626 - **Children's School:** 301-496-2077 - **Social Work:** 301-496-2381 (Local), 1-888-676-5668 (Toll-Free) - **Developmental Therapeutics Clinic:** 1-800-4-Cancer (1-800-422-6237) - **Patient Recruitment and Liaison Office:** 1-800-411-1222
What insurance does National Institutes of Health Clinical Center, 9000 Rockville Pike accept?
The National Institutes of Health Clinical Center accepts the Federal Employees Health Benefits (FEHB) program. The Foundation for the Advanced Education in the Sciences (FAES) partners with Trustmark and MetLife to provide medical/prescription, dental, and vision insurance plans for NIH Fellows and their families.
What awards or recognition has National Institutes of Health Clinical Center, 9000 Rockville Pike received?
The National Institutes of Health Clinical Center, located in Bethesda, Maryland, is a leading research hospital that has been awarded the 2011 Lasker~Bloomberg Public Service Award for its innovative therapy and transformation of scientific advances into practical applications. It receives significant funding for research and care, primarily through annual discretionary appropriations. Over 84% of the NIH budget supports extramural research, funding grants, contracts, and awards to universities and other research institutions.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.